Top Verified Suppliers of High-Purity 4-Amino-2,5-Difluorobenzoic Acid
- Technical Grade: Optimized for fluoroquinolone antibiotic synthesis with consistent molecular weight stability.
- Supply Security: Reliable bulk procurement channels ensuring uninterrupted production schedules.
- Quality Assurance: Comprehensive COA documentation verifying industrial purity standards above 98%.
In the realm of advanced pharmaceutical intermediates, the demand for fluorinated benzoic acid derivatives has surged due to their critical role in modern medicinal chemistry. Specifically, 4-Amino-2,5-Difluorobenzoic Acid (CAS 773108-64-8) serves as a pivotal building block for the development of next-generation fluoroquinolone antibiotics and kinase inhibitors. Procuring this material requires a partner who understands the complexities of fluorination chemistry and can deliver consistent industrial purity at scale. As a global manufacturer, the priority is not merely availability, but the reproducibility of synthesis parameters that affect downstream reaction yields.
When evaluating potential partners for bulk chemical sourcing, technical teams must look beyond basic catalog listings. The structural integrity of the difluoro-substituted aromatic ring is sensitive to harsh reaction conditions during upstream processing. Therefore, selecting a supplier with a robust manufacturing process is essential to minimize impurities such as unreacted starting materials or isomeric byproducts like 2,5-Difluoro-4-aminobenzoic acid variants that may complicate purification later in the drug substance workflow.
Technical Specifications and Synthesis Overview
The chemical profile of CAS 773108-64-8 demands precise handling. With a molecular formula of C7H5F2NO2 and a molecular weight of 173.12 g/mol, this compound exhibits specific physicochemical properties that influence its solubility and reactivity in coupling reactions. The presence of two fluorine atoms at the 2 and 5 positions significantly alters the electron density of the benzene ring, enhancing metabolic stability in the final pharmaceutical product.
A reliable synthesis route for this intermediate typically involves the nucleophilic aromatic substitution of corresponding chloro- or nitro- precursors, followed by careful reduction and hydrolysis steps. The control of temperature and pressure during these stages is vital to prevent defluorination, a common side reaction that degrades quality. High-performance liquid chromatography (HPLC) is standard for verifying the absence of mono-fluorinated impurities. Buyers seeking to optimize their own production lines should request detailed technical data packages that outline these process parameters.
For research and development teams requiring verified material for scale-up studies, accessing a dedicated product page is often the first step. When sourcing high-purity 4-Amino-2,5-Difluorobenzoic Acid, buyers should ensure the vendor provides batch-specific analytics that confirm melting point ranges and acidity coefficients (pKa). These data points are critical for predicting behavior in salt formation and crystallization processes.
Comparing Regional Production Capabilities
The global supply chain for specialized fluorinated intermediates is concentrated among a few key regions with advanced chemical infrastructure. Production capabilities vary significantly based on the availability of raw fluorinating agents and environmental compliance standards. Facilities located in major chemical hubs often benefit from integrated supply chains that reduce lead times and lower the bulk price per kilogram.
However, capacity alone is insufficient without quality oversight. Some regions may offer lower costs but struggle with consistency in industrial purity levels, leading to batch-to-batch variability that can halt clinical trial material production. It is imperative to audit the manufacturer's quality management system. NINGBO INNO PHARMCHEM CO.,LTD. stands out as a premier entity in this sector, leveraging state-of-the-art reactor systems to maintain strict control over exothermic reactions common in fluorination chemistry. This commitment ensures that every shipment meets the rigorous specifications required by regulatory bodies.
Evaluating Supply Chain Reliability and Export Documentation
Logistics and documentation are as critical as the chemical itself. A competent supplier must provide a comprehensive Certificate of Analysis (COA) with every shipment. This document should detail assay results, residual solvent analysis, and heavy metal content. For international transport, compliance with hazardous material regulations is non-negotiable, given the chemical nature of acidic organic compounds.
Transparency in the supply chain also extends to packaging integrity. While laboratory scales may utilize gram-level packaging, industrial clients require drum or tote configurations that protect the material from moisture and light degradation. Proper labeling according to GHS standards ensures safe handling upon receipt. Furthermore, a reliable partner will offer stability data to support shelf-life claims, ensuring that the material remains within specification during extended storage periods.
Physical and Chemical Properties
The following table outlines the standard technical specifications expected for high-grade material. Deviations from these norms should be investigated immediately upon receipt.
| Parameter | Specification |
|---|---|
| CAS Number | 773108-64-8 |
| Molecular Formula | C7H5F2NO2 |
| Molecular Weight | 173.12 g/mol |
| Appearance | Off-white to Light Yellow Crystalline Powder |
| Purity (HPLC) | > 98.0% |
| Boiling Point | ~316°C |
| Density | 1.536 g/cm³ |
| Flash Point | ~145°C |
| pKa | 3.59 ± 0.10 |
Conclusion
Securing a stable supply of fluorinated intermediates is a strategic decision that impacts the entire drug development timeline. Partnering with a dedicated global manufacturer like NINGBO INNO PHARMCHEM CO.,LTD. ensures access to materials produced under stringent quality controls. By prioritizing vendors who offer transparent COA documentation and proven manufacturing process capabilities, pharmaceutical companies can mitigate supply risks and focus on innovation. Whether for commercial scale production or early-stage research, the integrity of the starting material defines the success of the final synthesis.